SRT-100 Vision Sensus Healthcare INVESTOR OVERVIEW NASDAQ: SRTS November 2019 SCULPTURA Safe Harbor Statement Forward-Looking Statements This presentation includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these forwardlooking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," "potential" or, in ...

Start Time: 16:30 January 1, 0000 5:17 PM ET Sensus Healthcare, Inc. (NASDAQ:SRTS) Q3 2019 Earnings Conference Call November 06, 2019, 16:30 PM ET Company Participants Joe Sardano - Chairman and CEO Arthur Levine - CFO Kim Golodetz - SVP and Principal-LHA Conference Call Participants Will Fafinski - Craig-Hallum Andrew D’Silva - B. Riley FBR Anthony Vendetti - Maxim Group Faizzan Ahmad - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to your Sensus Healthcare 3Q 2019 Financial Results ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-37714 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) | Delaware | 27-1647271 ...

PART I [Item 1. Condensed Consolidated Financial Statements (Unaudited)](index=6&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20%28Unaudited%29) This section presents the unaudited condensed consolidated financial statements, including balance sheets, statements of operations, stockholders' equity, and cash flows, along with detailed notes explaining significant accounting policies, financial instrument details, and equity changes for Sensus Healthcare, Inc. for the periods ended June 30, 2019, and December 31, 2018 [Condensed Consolidated Balance Sheets](index=6&type=section&id=Balance%20Sheets%20as%20of%20June%2030%2C%202019%20and%20December%2031%2C%202018) Condensed Consolidated Balance Sheets | Metric | June 30, 2019 (unaudited) | December 31, 2018 | | :-------------------------------- | :------------------------ | :------------------ | | Cash and cash equivalents | $11,434,000 | $12,484,256 | | Accounts receivable, net | $12,216,835 | $13,145,934 | | Inventories | $2,101,295 | $1,628,817 | | Investment in debt securities | $5,391,908 | $2,892,190 | | Total Current Assets | $32,855,378 | $31,902,191 | | Total Assets | $35,849,458 | $33,251,229 | | Accounts payable and accrued expenses | $4,570,583 | $5,166,239 | | Deferred revenue, current portion | $979,409 | $722,025 | | Total Current Liabilities | $6,028,171 | $6,024,481 | | Total Liabilities | $8,464,988 | $6,791,213 | | Total Stockholders' Equity | $27,384,470 | $26,460,016 | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Statements%20of%20Operations%20for%20the%20Three%20and%20Six%20Months%20Ended%20June%2030%2C%202019%20and%202018) Condensed Consolidated Statements of Operations | Metric | Three Months Ended June 30, 2019 | Three Months Ended June 30, 2018 | Six Months Ended June 30, 2019 | Six Months Ended June 30, 2018 | | :----------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Revenues | $7,476,296 | $6,056,735 | $12,912,895 | $12,012,197 | | Cost of Sales | $2,537,102 | $2,116,108 | $4,657,723 | $4,131,308 | | Gross Profit | $4,939,194 | $3,940,627 | $8,255,172 | $7,880,889 | | Total Operating Expenses | $4,893,711 | $4,439,357 | $10,402,725 | $9,494,138 | | Income (Loss) From Operations | $45,483 | $(498,730) | $(2,147,553) | $(1,613,249) | | Net Income (Loss) | $112,308 | $(540,651) | $(2,008,710) | $(1,666,563) | | Net Income (Loss) per share – Basic | $0.01 | $(0.04) | $(0.12) | $(0.12) | | Net Income (Loss) per share – Diluted | $0.01 | $(0.04) | $(0.12) | $(0.12) | [Condensed Consolidated Statements of Stockholders' Equity](index=8&type=section&id=Statements%20of%20Stockholders%27%20Equity%20for%20the%20Three%20and%20Six%20Months%20Ended%20June%2030%2C%202019%20and%202018) Condensed Consolidated Statements of Stockholders' Equity | Metric | December 31, 2018 | June 30, 2019 (unaudited) | | :-------------------------------- | :------------------ | :------------------------ | | Common Stock (Shares) | 16,145,915 | 16,551,728 | | Common Stock (Amount) | $161,459 | $165,517 | | Additional Paid-In Capital | $39,957,905 | $43,005,765 | | Treasury Stock (Shares) | (33,454) | (54,698) | | Treasury Stock (Amount) | $(133,816) | $(252,570) | | Accumulated Deficit | $(13,525,532) | $(15,534,242) | | Total Stockholders' Equity | $26,460,016 | $27,384,470 | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Statements%20of%20Cash%20Flows%20for%20the%20Six%20Months%20Ended%20June%2030%2C%202019%20and%202018) Condensed Consolidated Statements of Cash Flows | Cash Flow Activity | Six Months Ended June 30, 2019 | Six Months Ended June 30, 2018 | | :--------------------------------------- | :------------------------------- | :------------------------------- | | Net Cash Used In Operating Activities | $(941,596) | $(4,689,893) | | Net Cash Provided By (Used) In Investing Activities | $(2,729,144) | $647,890 | | Net Cash Provided By Financing Activities | $2,620,484 | $1,969,311 | | Net Decrease in Cash and Cash Equivalents | $(1,050,256) | $(2,072,692) | | Cash and Cash Equivalents – Ending | $11,434,000 | $8,012,776 | [Notes to the Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) [Note 1 — Organization and Summary of Significant Accounting Policies](index=10&type=section&id=Note%201%20%E2%80%94%20Organization%20and%20Summary%20of%20Significant%20Accounting%20Policies) - Sensus Healthcare, Inc. manufactures radiation therapy devices as a single segment from its Florida headquarters, establishing an Israeli subsidiary in February 2018[27](index=27&type=chunk) - The Company adopted ASC Topic 606 on January 1, 2018, using the modified retrospective method, with no significant alteration to historical revenue recognition policies[31](index=31&type=chunk) Disaggregated Revenue (Product vs. Service) | Revenue Type | Three Months Ended June 30, 2019 | Three Months Ended June 30, 2018 | Six Months Ended June 30, 2019 | Six Months Ended June 30, 2018 | | :------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Product Revenue | $6,969,527 | $5,507,134 | $11,900,452 | $11,039,781 | | Service Revenue | $506,769 | $549,601 | $1,012,443 | $972,416 | | Total Revenue | $7,476,296 | $6,056,735 | $12,912,895 | $12,012,197 | - Revenue is highly concentrated in the United States, comprising **91% and 86%** of total revenues for the three and six months ended June 30, 2019, respectively, with one U.S. customer accounting for **70% and 64%** of revenues for the same periods[38](index=38&type=chunk) - Adoption of ASU No. 2016-02 in Q1 2019 resulted in approximately **$805,000** in operating lease right-of-use assets and liabilities, without material impact on liquidity or operations[49](index=49&type=chunk) [Note 2 — Property and Equipment](index=14&type=section&id=Note%202%20%E2%80%94%20Property%20and%20Equipment) Property and Equipment, Net | Category | June 30, 2019 (unaudited) | December 31, 2018 | | :------------------------ | :------------------------ | :------------------ | | Operations equipment | $1,062,643 | $852,273 | | Tradeshow and demo equipment | $818,232 | $784,244 | | Computer equipment | $119,127 | $112,521 | | Less accumulated depreciation | $(1,061,092) | $(858,009) | | Property and Equipment, Net | $938,910 | $891,029 | - Depreciation expense was approximately **$129,000** and **$109,000** for the three months ended June 30, 2019 and 2018, and **$233,000** and **$185,000** for the six months ended June 30, 2019 and 2018, respectively[50](index=50&type=chunk) [Note 3 — Patent Rights](index=14&type=section&id=Note%203%20%E2%80%94%20Patent%20Rights) Patent Rights, Net | Category | June 30, 2019 (unaudited) | December 31, 2018 | | :---------------------- | :------------------------ | :------------------ | | Gross carrying amount | $1,253,018 | $1,253,018 | | Less accumulated amortization | $(867,474) | $(819,281) | | Patent Rights, Net | $385,544 | $433,737 | - Amortization expense was approximately **$24,000** for both three-month periods and **$48,000** for both six-month periods ended June 30, 2019 and 2018[51](index=51&type=chunk) [Note 4 — Revolving Credit Facility](index=15&type=section&id=Note%204%20%E2%80%94%20Revolving%20Credit%20Facility) - The revolving credit facility, amended in October 2017, extends maturity to October 31, 2019, with availability up to **$5 million** or the borrowing base plus a **$2.5 million** non-formula sublimit[52](index=52&type=chunk) - Interest rates are Prime plus **0.75%** (**6.25%** at June 30, 2019) and Prime plus **1.50%** (**7.00%** at June 30, 2019) on non-formula borrowings, with no outstanding borrowings and covenant compliance[53](index=53&type=chunk) [Note 5 — Product Warranties](index=15&type=section&id=Note%205%20%E2%80%94%20Product%20Warranties) Changes in Product Warranty Liability (Six Months Ended June 30, 2019) | Activity | Amount | | :-------------------------- | :------- | | Balance, beginning of period | $136,217 | | Warranties accrued | $116,402 | | Payments on warranty claims | $(103,643) | | Balance, end of period | $148,976 | [Note 6 — Leases](index=15&type=section&id=Note%206%20%E2%80%94%20Leases) - The Company renewed its headquarters lease until September 2022, while its Israeli subsidiary secured a two-year office lease in September 2018 and a 10-year manufacturing facility lease in April 2019, including a four-month rent-free period[55](index=55&type=chunk)[56](index=56&type=chunk) Maturity of Operating Lease Liabilities (as of June 30, 2019) | Year | Amount | | :-------------------------- | :------- | | 2019 (July 1 – Dec 31) | $175,890 | | 2020 | $358,787 | | 2021 | $348,122 | | 2022 | $284,578 | | 2023 | $104,343 | | Thereafter | $600,575 | | Total undiscounted payments | $1,872,295 | | Less: Imputed interest | $(293,019) | | Present Value of Liabilities | $1,579,276 | - As of June 30, 2019, the weighted-average remaining lease term is **6.6 years** and the discount rate is **5.0%**, with an initial ROU asset of approximately **$805,000** recognized upon lease standard adoption[60](index=60&type=chunk) [Note 7 — Commitments and Contingencies](index=16&type=section&id=Note%207%20%E2%80%94%20Commitments%20and%20Contingencies) - The Company's annual contract manufacturing agreement for SRT-100 and SRT-100 Vision products resulted in purchases of approximately **$3,730,000** for the six months ended June 30, 2019, an increase from **$1,825,000** in the prior year[61](index=61&type=chunk)[62](index=62&type=chunk) - The Company is cooperating with a Department of Justice investigation into a physician's Medicare billing for SRT-100 use, disputing wrongdoing and asserting strong defenses as it does not submit claims or provide billing advice[65](index=65&type=chunk) [Note 8 — Employee Benefit Plans](index=17&type=section&id=Note%208%20%E2%80%94%20Employee%20Benefit%20Plans) - The Company's 401(k) defined contribution plan incurred expenses of approximately **$55,000** for the six months ended June 30, 2019, compared to **$48,000** in the prior year[66](index=66&type=chunk) [Note 9 — Stockholders' Equity](index=17&type=section&id=Note%209%20%E2%80%94%20Stockholders%27%20Equity) - As of June 30, 2019, **16,551,728** shares of common stock were issued, with **16,497,030** shares outstanding[67](index=67&type=chunk) - Investor warrants from the 2016 IPO for **2,300,000** shares at **$6.75** were extended to June 8, 2020, with **405,813** shares exercised during the first two quarters of 2019[69](index=69&type=chunk) Warrant Activity Summary | Metric | December 31, 2018 | June 30, 2019 | | :-------------------------- | :------------------ | :-------------- | | Number of Warrants Outstanding | 2,438,000 | 2,032,187 | | Weighted Average Exercise Price | $6.75 | $6.75 | | Weighted Average Remaining Contractual Term (Years) | 0.55 | 1.01 | | Intrinsic Value of Warrants | $1,609,000 | $0 | - Unrecognized stock compensation expense totaled approximately **$1,075,000** as of June 30, 2019, to be recognized over the remaining vesting period[79](index=79&type=chunk) Restricted Stock Activity | Metric | Shares | Weighted Average Grant Date Fair Value | | :-------------------------- | :----- | :------------------------------------- | | Unvested balance at Dec 31, 2018 | 165,834 | $5.84 | | Vested | (66,667) | $5.24 | | Unvested balance at June 30, 2019 | 99,167 | $6.24 | Stock Option Activity | Metric | Number of Options | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (Years) | | :-------------------------- | :---------------- | :------------------------------ | :------------------------------------------------ | | Outstanding – Dec 31, 2018 | 229,334 | $5.55 | 9.08 | | Outstanding – June 30, 2019 | 229,334 | $5.55 | 8.58 | | Exercisable – June 30, 2019 | 57,334 | $5.55 | 8.58 | [Note 10 — Income Taxes](index=20&type=section&id=Note%2010%20%E2%80%94%20Income%20Taxes) - The Company reported a book loss before taxes for the six months ended June 30, 2019, resulting in **$0** tax expense for both 2019 and 2018, with no uncertain tax positions requiring recognition[81](index=81&type=chunk)[82](index=82&type=chunk) [Note 11 — Subsequent Events](index=20&type=section&id=Note%2011%20%E2%80%94%20Subsequent%20Events) - No subsequent events requiring adjustment or disclosure in the financial statements were identified[85](index=85&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on the Company's financial condition and results of operations, highlighting revenue growth driven by higher-priced products, increased operating expenses due to R&D and headcount, and changes in cash flows, also discussing liquidity, capital resources, and status as an emerging growth company [Overview](index=22&type=section&id=Overview) - Sensus Healthcare, Inc. is a medical device company specializing in non-invasive, cost-effective superficial radiation therapy (SRT) for skin conditions[88](index=88&type=chunk) - In February 2019, the Company received FDA clearance for Sculptura™, a robotic radiation oncology system for targeted intraoperative radiotherapy and Brachytherapy[88](index=88&type=chunk) [Results of Operations](index=23&type=section&id=Results%20of%20Operations) Key Financial Highlights (YoY Comparison) | Metric | 3 Months Ended June 30, 2019 | 3 Months Ended June 30, 2018 | YoY Change (%) | 6 Months Ended June 30, 2019 | 6 Months Ended June 30, 2018 | YoY Change (%) | | :----------------------------- | :--------------------------- | :--------------------------- | :------------- | :--------------------------- | :--------------------------- | :------------- | | Revenues | $7,476,296 | $6,056,735 | 23.4% | $12,912,895 | $12,012,197 | 7.5% | | Cost of Sales | $2,537,102 | $2,116,108 | 19.9% | $4,657,723 | $4,131,308 | 12.7% | | Gross Profit | $4,939,194 | $3,940,627 | 25.3% | $8,255,172 | $7,880,889 | 4.7% | | Gross Profit Percentage | 66.1% | 65.1% | 1.0 pp | 63.9% | 65.6% | -1.7 pp | | Selling and marketing | $1,995,263 | $1,960,309 | 1.8% | $4,525,608 | $4,175,220 | 8.4% | | General and administrative | $963,641 | $913,624 | 5.5% | $1,976,803 | $2,255,876 | -12.4% | | Research and development | $1,934,807 | $1,565,424 | 23.6% | $3,900,314 | $3,063,042 | 27.3% | | Income (Loss) From Operations | $45,483 | $(498,730) | N/A | $(2,147,553) | $(1,613,249) | N/A | | Net Income (Loss) | $112,308 | $(540,651) | N/A | $(2,008,710) | $(1,666,563) | N/A | - Revenue increased for the three months due to higher SRT-100 Vision product sales, while six-month revenue growth was primarily driven by an increase in product average selling price[92](index=92&type=chunk)[99](index=99&type=chunk) - Gross profit percentage increased for the three months due to higher-margin Vision product sales but decreased for the six months due to product mix[94](index=94&type=chunk)[101](index=101&type=chunk) - Research and development expenses significantly increased for both periods, primarily due to Sculptura's production ramp and FDA clearance[97](index=97&type=chunk)[104](index=104&type=chunk) - General and administrative expenses decreased for the six-month period, primarily due to a non-recurring prior-year stock compensation expense, partially offset by increased professional fees[103](index=103&type=chunk) [Financial Condition](index=24&type=section&id=Financial%20Condition) - Cash, cash equivalents, and investment balance increased to **$16.8 million** at June 30, 2019, from **$15.4 million** at December 31, 2018, driven by **$2.7 million** from exercised warrants, partially offset by **$0.9 million** cash used in operating activities[106](index=106&type=chunk) - No borrowings were outstanding under the revolving line of credit at June 30, 2019, or December 31, 2018[107](index=107&type=chunk) [Liquidity and Capital Resources](index=24&type=section&id=Liquidity%20and%20Capital%20Resources) - Primary short-term capital needs include expenditures for expanding sales, marketing, distribution, and research and development activities[108](index=108&type=chunk) Summary of Cash Flows (Six Months Ended June 30) | Cash Flow Activity | 2019 | 2018 | | :-------------------------- | :----------- | :----------- | | Operating Activities | $(941,596) | $(4,689,893) | | Investing Activities | $(2,729,144) | $647,890 | | Financing Activities | $2,620,484 | $1,969,311 | | Total Net Cash Flow | $(1,050,256) | $(2,072,692) | - Net cash used in operating activities significantly decreased in 2019 due to reduced net operating assets and non-cash charges, contrasting with 2018's higher operating loss and increased accounts receivable[111](index=111&type=chunk) - Net cash used in investing activities in 2019 stemmed primarily from net investments in debt securities, whereas 2018 saw net cash provided by matured debt securities[112](index=112&type=chunk) - Net cash provided by financing activities in 2019 primarily resulted from investor warrant exercises, while 2018's cash was mainly from revolving credit facility borrowings[113](index=113&type=chunk) - The Company filed a universal shelf registration statement to offer up to **$20 million** of securities, not subject to the 'baby shelf' rule due to its public float exceeding **$75 million**[114](index=114&type=chunk) [Critical Accounting Policies and Estimates](index=26&type=section&id=Critical%20Accounting%20Policies%20and%20Estimates) - The Company's financial statements adhere to GAAP, with critical accounting policies detailed in the notes and the Annual Report on Form 10-K[117](index=117&type=chunk) [JOBS Act](index=26&type=section&id=JOBS%20Act) - As an "emerging growth company" under the JOBS Act, the Company benefits from reduced reporting obligations, including exemptions from auditor attestation and executive compensation disclosures[118](index=118&type=chunk) - The Company opted out of the extended transition period for new accounting standards, committing to comply on the same dates as non-emerging growth companies[119](index=119&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=26&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) This section states that there are no quantitative and qualitative disclosures about market risk applicable to the Company for the reporting period - This item is not applicable to the Company[120](index=120&type=chunk) [Item 4. Controls and Procedures](index=26&type=section&id=Item%204.%20Controls%20and%20Procedures) This section confirms the effectiveness of the Company's disclosure controls and procedures and reports no significant changes in internal control over financial reporting during the quarter [Evaluation of Disclosure Control and Procedures](index=26&type=section&id=Evaluation%20of%20Disclosure%20Control%20and%20Procedures) - Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of June 30, 2019[121](index=121&type=chunk) [Changes in Internal Control over Financial Reporting](index=26&type=section&id=Changes%20in%20Internal%20Control%20over%20Financial%20Reporting) - No significant changes occurred in the Company's internal control over financial reporting during the most recently completed fiscal quarter[122](index=122&type=chunk) PART II [Item 1. Legal Proceedings](index=27&type=section&id=Item%201.%20Legal%20Proceedings) This section refers to Note 7 of the financial statements for details on legal proceedings, indicating the Company is involved in ordinary course legal matters and assesses the need for liability recording - The Company is involved in ordinary course legal proceedings, assessing the need to record liabilities for litigation and contingencies as detailed in Note 7[124](index=124&type=chunk) [Item 1A. Risk Factors](index=27&type=section&id=Item%201A.%20Risk%20Factors) This section incorporates by reference the risk factors previously disclosed in the Company's Form 10-K, stating that no material changes have occurred since its filing - Risk factors remain as disclosed in the Form 10-K for the year ended December 31, 2018, with no material changes reported in this Quarterly Report on Form 10-Q[125](index=125&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=27&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section confirms that there were no unregistered sales of equity securities, no use of proceeds from registered securities, and no purchases of equity securities by the registrant during the three months ended June 30, 2019 - No unregistered sales of securities occurred during the three months ended June 30, 2019[126](index=126&type=chunk) - No proceeds were used from the sale of registered securities[127](index=127&type=chunk) - No equity securities were purchased by the registrant or affiliated purchasers[128](index=128&type=chunk) [Item 3. Defaults Upon Senior Securities](index=27&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This section states that there were no defaults upon senior securities during the reporting period - No defaults occurred upon senior securities[129](index=129&type=chunk) [Item 4. Mine Safety Disclosure](index=27&type=section&id=Item%204.%20Mine%20Safety%20Disclosure) This section indicates that mine safety disclosure is not applicable to the Company - Mine Safety Disclosure is not applicable to the Company[130](index=130&type=chunk) [Item 5. Other Information](index=27&type=section&id=Item%205.%20Other%20Information) This section states that there is no other information to report - No other information is reported[131](index=131&type=chunk) [Item 6. Exhibits](index=28&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed as part of the Quarterly Report on Form 10-Q, including an amendment to the Warrant Agreement, certifications, and XBRL documents - Exhibits include Amendment No. 1 to Warrant Agreement, CEO and CFO certifications (pursuant to Rule 13a-14(a) and 18 U.S.C. Section 1350), and various XBRL taxonomy documents[133](index=133&type=chunk) [Signatures](index=29&type=section&id=Signatures) This section contains the duly authorized signatures of Sensus Healthcare, Inc.'s Chief Executive Officer and Chief Financial Officer, certifying the report - The report is signed by Joseph C. Sardano, Chief Executive Officer, and Arthur Levine, Chief Financial Officer, on August 12, 2019[137](index=137&type=chunk)

Financial Data and Key Metrics Changes - Revenues for Q2 2019 were $7.5 million, up 23% from Q2 2018, and significantly above Q1 2019 revenues of $5.4 million [20][21] - Gross profit for Q2 2019 was $4.9 million, representing 66.1% of revenues, compared to $3.9 million or 65.1% for Q2 2018 [20][21] - Net income for Q2 2019 was $0.1 million or $0.01 per diluted share, compared to a net loss of $0.5 million or $0.04 per share for Q2 2018 [25] Business Line Data and Key Metrics Changes - The company shipped 22 systems in total during Q2 2019, including 17 SRT-100 Vision systems, indicating a recovery in sales [7][20] - The SRT-100 Vision system sales were a significant contributor to revenue growth, with a focus on expanding the customer base to large dermatology practices and hospital centers [9][32] Market Data and Key Metrics Changes - The company is targeting a market consisting of approximately 14,000 dermatologists and 1,000 Mohs surgeons in the U.S., representing over 7,500 offices [32] - The inclusion of SRT products in Premier Healthcare Alliance's approved products list is expected to enhance market penetration [13] Company Strategy and Development Direction - The company is focused on expanding its SRT customer base and enhancing its product offerings, including the unique Sentinel IP product for asset management [10][12] - The Sculptura Modulated Robotic Brachytherapy system is being actively marketed, with collaborations with medical institutions to support its launch [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the second half of the year, citing a resumption of sales to a key customer and ongoing efforts to work with multisite customers [32] - The company anticipates positive developments in reimbursement codes, particularly with the main code 77401 scheduled for revaluation in 2021 [17][19] Other Important Information - Cash and investments as of June 30, 2019, were $16.8 million, an increase from $15.4 million at the end of 2018, with no outstanding borrowings [27] - The company expects to increase sales and marketing expenses in Q3 2019 due to trade show costs and the Sculptura launch [22] Q&A Session Summary Question: Changes with the large turnkey partner - Management confirmed the renewal of the contract with SkinCure and ongoing discussions regarding terms and conditions [38] Question: Resolution of DOJ CID from a few years back - Management reported no follow-up news or issues related to the DOJ CID [44] Question: Timeline for Sculptura data from institutions - Management indicated ongoing collaboration with UPenn and efforts to gather data ahead of the ASTRO conference [45][46] Question: Expectations for aesthetic products from Israel - Management stated that aesthetic products are on track for FDA approval, with a focus on quality and differentiation [52] Question: Current reimbursement rates and future expectations - Current reimbursement for SRT is approximately $2,000 to $2,100 for an episode of care, with expectations for revaluation in 2021 [57][58]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-37714 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1647271 (State ...

Sensus Healthcare's (NASDAQ:SRTS) Q1 2019 Earnings Conference Call May 9, 2019 5:00 PM ET Company Participants Arthur Levine - CFO Joseph Sardano - Chairman, CEO & President Kim Golodetz - SVP and Principal Conference Call Participants Brendan Popson - Northcoast Research Partners, LLC Christopher Paul McGinnis - Sidoti & Company, LLC Operator Good day and welcome to the Sensus Healthcare First Quarter Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to tu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________ TO ____________ Commission File Number: 001-37714 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1647271 (State or ot ...

Sensus Healthcare (NASDAQ:SRTS) Q4 2018 Earnings Conference Call February 14, 2019 4:30 PM ET Company Participants Kim Golodetz – LHA Investor Relations Joe Sardano – Chief Executive Officer Arthur Levine – Chief Financial Officer Conference Call Participants Alex Nowak – Craig-Hallum Capital Group Andrew D’Silva – B. Riley FBR Anthony Vendetti – Maxim Group Ben Haynor – Alliance Global Partners Scott Henry – ROTH Capital Yi Chen – H.C. Wainwright Marcel Herbst – Herbst Capital Management Operator Good afte ...